Placebo controlled,randomised,crossover study of the efficacy of bosentan in the management of patients with Coronary Slow Flow Phenemenon

Study of bosentan in the management of angina in patients with Coronary Slow Flow phenomenon

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12608000236392

Acronym

Nil

Enrollment

Registered

2008-05-08

Start date

2007-05-28

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Bosentan 125mgs orally twice daily for 4 weeks with 1 week washout prior to crossover

Study design

Allocation

Randomised controlled trial

Intervention model

Crossover

Primary purpose

Treatment

Masking

Blinded (masking used)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Coronary Slow Flow Phenomenon. Angina frquency>3 episodes/week

Exclusion criteria

Pulmonary hypertension,liver disease.Cyclosporin,glibenclamide,ketoconazole

Outcome results